Shield Therapeutics yesterday issued a trading statement indicating that it recorded modest initial revenues of £1.5mln, comprising £0.1mln of net product sales from US commercial activities, £0.9mln of royalties from sales by Norgine in the EU and milestones of £0.5mln. The market marked the share
18 Feb 2022
Trading update confirms early commercial progress
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Trading update confirms early commercial progress
Shield Therapeutics Plc (STX:LON) | 1.4 0 (-1.8%) | Mkt Cap: 10.8m
- Published:
18 Feb 2022 -
Author:
Robin Davison | John Savin PhD -
Pages:
5
Shield Therapeutics yesterday issued a trading statement indicating that it recorded modest initial revenues of £1.5mln, comprising £0.1mln of net product sales from US commercial activities, £0.9mln of royalties from sales by Norgine in the EU and milestones of £0.5mln. The market marked the share